From Nasdaq: 2025-02-22 07:15:00

Gilead Sciences Inc. (NASDAQ: GILD) stock hit a 52-week high at $106.69 after robust Q4 2024 earnings. The company defended its controversial $84,000 hep C treatment, Sovaldi, in 2013, but faced competition from AbbVie Inc. afterward. Gilead reported earnings of $1.90 per share, surpassing estimates, and raised guidance for 2025.

In 2024, Gilead’s HIV, Oncology, and Liver Disease sales grew significantly. Its HIV vaccine, Lenacapavir, achieved 100% effectiveness and is set to launch in the summer of 2025. GILD stock formed a bull flag breakout pattern, hitting a 52-week high at $106.69. Analysts have a consensus price target of $101.33, with the highest target at $125.

Gilead’s stock surge is attributed to its strong financial performance, innovative product portfolio, and breakthrough HIV treatment. The company’s potential for growth and new product launches, such as the 100% effective Lenacapavir vaccine, have contributed to investor interest. Gilead’s stock is currently in a bull trend, with a 52-week high at $106.69.



Read more at Nasdaq:: Gilead Sciences: 4 Reasons This Stock Has Much More To Rise